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cancer patients irrespective of drug is identiﬁed. The estimate combines the prediction 
of number of newly diagnosed and treated patients with the prediction of number of 
patients who were diagnosed previously and would probably be treated in a given 
year due to a relapse or progression of the primary malignant disease. In the second 
step patients are localised to individual drugs according to treatment scheme provided 
by the panel of experts, adjusted using information from clinical registries. RESULTS: 
The model currently provides predictions of potentially treated patients with quanti-
ﬁed uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) 
patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving 
bevacizumab for colorectal cancer, 300 (151; 449) patients receiving cetuximab for 
colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell 
lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number 
of patients requiring targeted anticancer therapy in the years to come. Final outcome 
is used by decision makers for planning of health care expenses in the Czech 
Republic.
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OBJECTIVES: The aim of this analysis is to compare the reimbursement rates for 
administration costs of triplet therapy bevacizumab-cisplatin-gemcitabine (BCG) 
versus doublet therapy cisplatin-pemetrexed (CP) for mNSCLC patients in France and 
German health care systems. METHODS: A systematic literature search performed 
in Medline, Embase, Cochrane, and Centre of Reviews and Dissemination databases 
identiﬁed 578 publications of anticancer agents. In addition, an evaluation of national 
reimbursement tariffs in both inpatient and outpatient settings was performed. 
Country-speciﬁc reimbursement structures were veriﬁed by two in-depth semi-struc-
tured expert oncologist interviews in each country. RESULTS: No publication includ-
ing reimbursement tariffs for the administration of anticancer agents was identiﬁed 
during the systematic literature review. The evaluation of the national reimbursement 
tariffs showed signiﬁcant costs for the administration service. The French GHS # 9606 
“Chimiothérapie pour tumeur, en séances” is the reimbursement tariff of one inpatient 
chemotherapy session valued at a385.77 (public sector). The chemotherapy home 
infusion tariff code “chemotherapy, intravenous treatment” is valued at a374.16 
irrespective of the number of injections administered. In Germany the inpatient 
 reimbursement tariff G-DRG # E71B “Neubildung der Atmungsorgane” refers to the 
indication “neoplasm” with a cost of a1.671 for an inpatient visit and a610.40 for 
an outpatient visit. In both reimbursement systems these are ﬂat rates irrespective of 
the number of chemotherapeutic drugs administered. CONCLUSIONS: When com-
paring the reimbursement for administrations of anticancer treatment combinations 
in France and Germany administration costs are unaffected by single, double or triple 
chemotherapy combinations. Therefore there is no difference in the cost of reimburse-
ment for administration for BCG versus CP.
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OBJECTIVES: Despite implementation of radical cost control measures, pharmaceuti-
cal expenditure is expected to keep increasing due to highly innovative, expensive 
drugs, including immunotherapeutics. The objective of this study was to understand 
how different markets are responding to cost containment pressures, using a compare-
and-contrast approach of reimbursement decisions for three recently approved treat-
ments for metastatic renal cell carcinoma (mRCC). Based on the ﬁndings we propose 
fundamentals to build acceptable reimbursement strategies for AI, including cancer 
vaccines. METHODS: We examined commonalities and differences of three drugs 
for mRCC, assessing drug costs, health technology assessments (HTA), and reimburse-
ment decisions across 7 countries with similar pharmaceutical funding schemes 
(Canada, France, Germany, Italy, Spain, Sweden, and the UK). In each of the 7 coun-
tries primary reimbursement criteria for these drugs were identiﬁed, local HTAs were 
reviewed, and speciﬁc qualitative research with local payers and experts was con-
ducted. For country comparisons, drug treatment costs were calculated from a payer 
perspective (6 weeks therapy). RESULTS: Treatment cost differences in the seven 
countries were minimal and mostly related to exchange rates indicating that, for 
innovative drugs, price convergence has been achieved in these countries. More than 
70% of the total HTA evaluations conducted involved immunotherapeutics. Only the 
SMC assessment recommended against the use of the 3 studied drugs. Most countries 
apply or are studying some type of risk sharing scheme or access/restriction program 
for forthcoming drugs. CONCLUSIONS: Most payers accept high priced drugs; 
however, they certainly restrict patient access or set up different types of agreements 
with suppliers to be able to maintain budget control. Current reimbursement schemes 
in the countries studied will need to evolve according to similar parameters in order 
to give access to highly complex therapies as AI. In each country, the feasibility of 
implementing processes to track drug use, cost and outcomes will determine how these 
reimbursement schemes develop.
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OBJECTIVES: Colorectal cancer (CRC) is the third leading cause of cancer mortality 
in the US with disparities in risk between rural and urban patients. The aim of the 
study was to: 1) describe the characteristics of hospital admissions, 2) compare the 
length of stay and in-hospital deaths in rural and urban West Virginia residents with 
a primary diagnosis of CRC. METHODS: Data from the Health Care Cost and 
 Utilization Project, State Inpatient Database for the years 2003, 2005, 2006 and 
2007 were used to perform analyses of all discharges with a primary diagnosis of 
CRC. Chi square tests compared categorical descriptive statistics between rural and 
urban cases. One-way ANOVA compared mean length of stay based on rural-urban 
category. RESULTS: Admissions for CRC as a primary diagnosis decreased constantly 
from 882 in 2003 to 787 in 2007. In-hospital deaths rose steadily from 5.1% in 2003 
to 7% in 2006, but fell to 5.7% in 2007. Mean ages ranged between 69.6 years and 
70.3 years and percentage of female admissions ranged between 53.1% and 55.2% 
over the four years. A greater proportion of patients from large metros (17.4%) died 
in-hospital compared to small metros (7.0%), micropolitan (4.4%) and rural (5.2%) 
areas (p  0.001). Leading primary payer was Medicare for all four locations. Rural 
patients had the shortest mean length of stay (9.0 days). The mean length of stay dif-
fered signiﬁcantly between rural (9.0 days) and micropolitan (10.0 days) patients. 
CONCLUSIONS: Colorectal cancer provides a signiﬁcant burden to the health care 
system in West Virginia. Unlike previously reported in certain other states and coun-
tries, a greater proportion of urban residents in West Virginia are dying in-hospital 
due to CRC. The reasons for these disparities go beyond demographic differences 
between rural-urban residents and need to be explored.
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OBJECTIVES: Chemotherapy-induced vomiting (CIV) is a frequent side effect of 
cancer treatment, with debilitating symptoms and negative effects on quality of life. 
CIV may be acute (within 24 hours of chemotherapy) or delayed (up to 7 days later). 
Different doses of PAL are available but the ideal one is still unknown. A recent meta-
analysis demonstrated that PAL is more effective than other serotonin inhibitors in 
preventing nausea and CIV in patients receiving MoHE chemotherapy. We aimed to 
perform a SR and MA of all randomized controlled trials (RCT) comparing PAL 
0.25 mg (or 0.3–1 mcg/kg) to PAL 0.75 mg (or 10 mcg/kg) as single intravenous doses 
in this setting of patients. METHODS: We searched several databases: MEDLINE, 
EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of 
acute and delayed vomiting. The side effects of each treatment were analyzed. A sub-
group analysis was planned and performed to evaluate the inﬂuence of the use of 
corticosteroids. The results of individual studies were pooled in MA, using the 
RevMan 5.1 software. The results are expressed as Risk Ratio (RR) and the corre-
spondent 95% Conﬁdence Interval (CI). RESULTS: Eight studies with 1674 patients 
were included. There was no difference between the efﬁcacy of the evaluated doses in 
preventing either acute (RR  1.04; CI  95%  0.91 to 1.18; p  0.60) or delayed 
vomiting (RR  1.01; CI95%  0.90 to 1.13; p  0.89). There were no differences in 
side effects either: headache (RR  0.88; CI95%  0.64 to 1.20; p  0.41), dizziness 
(RR  1.20; CI95%  0.33 to 4.35; p  0.78), constipation (RR  0.67; CI95%  
0.42 to 1.06; p  0.09) or diarrhea (RR  1.51; CI95%  0.43 to 5.31; p  0.52). The 
subgroup analysis found that the addition of corticosteroids had no impact on the 
efﬁcacy of PAL. CONCLUSIONS: Both doses of PAL have equal efﬁcacy and safety 
proﬁle in preventing CIV in patients receiving MoHE chemotherapy. The choice of 
scheme, in this situation, must be the least costly one.
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OBJECTIVES: To perform a review of the published meta-analyses, systematic reviews 
and health technology assessments reports (HTAR) which evaluated the use of ritux-
imab for the treatment of non-Hodgkin lymphoma (NHL) regarding its beneﬁts, safety 
proﬁle and cost-effectiveness. METHODS: A search of MEDLINE, Lilacs, Cochrane 
library, Web of science and INAHTA websites from 1990 to 2009 was conducted. 
The following MESH terms were used: “Meta-Analysis”, “Systematic Reviews”, 
“Lymphoma, Non-Hodgkin”, “Lymphoma, Large B-Cell, Diffuse” and “rituximab”. 
Included studies were those which evaluated the use of rituximab alone and/or in 
combination with other therapies in ﬁrst line, second line and maintenance therapy 
for naive, refractory patients or relapsed disease in different patient characteristics. 
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RESULTS: A total of six systematic reviews (SR) were found and met our inclusion 
criteria. For the indolent indication: a) Wake et al. 2002 and Schulz et al. 2007 evalu-
ated the treatment as ﬁrst line or subsequent therapies; b) Vidal et al. 2009 and Aksoy 
et al. 2009 assessed the maintenance therapy; c) Cheung et al. 2007 evaluated: ﬁrst 
line and subsequent therapies, maintenance and aggressive NHL; and d) Knight et al. 
2004 evaluated aggressive NHL. Only three studies developed a meta-analysis (Vidal, 
Schulz and Aksoy). According to the SRs rituximab induced remission, improved 
overall survival and disease control. Twenty ﬁve HTAR were found: 5 indicated the 
analysis through inexistent links; 2 belonged to sites with content blocked to non-
members; 2 related to other drugs; 3 indicated ongoing analysis; 3 related to other 
indications. Consequently, 10 reports met the survey criteria. Seven out of 10 pub-
lished HTAR support the use of rituximab for indolent or aggressive lymphomas. 
There are three assessments which are not conclusive. CONCLUSIONS: Findings from 
systematic reviews suggest that rituximab offer better clinical outcomes to patients. 
Most of the Health Technology Assessment reports indicate rituximab as a cost-
 effective alternative.
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OBJECTIVES: The use of Trastuzumab (T) for the adjuvant treatment of breast cancer 
patients (BCP) has been tested in clinical trials. Our goal is to perform a health tech-
nology evaluation in order to stablish if the scientiﬁc evidences are strong enough to 
support the use of T and to compare its cost-effectiveness ratio (CER) with other 
treatments covered by the public sector in Brazil. METHODS: We performed a litera-
ture search, looking for randomized controlled clinical trials (RCTs), systematic 
reviews (SR), guidelines, pharmacoeconomic analysis and endorsements from regula-
tory agencies on the use of T for BCP. RESULTS: We found ﬁve RCTs, three SR, six 
guidelines / health technology assessments and three endorsements from regulatory 
agencies. Four RCTs tested Trastuzumab 2 mg/kg/week or 6 mg/kg/ every 3 weeks 
during one year, in patients with tumors  1 cm. All of these showed a 50% reduction 
on risk of relapse and a 40% reduction in death risk. SR conﬁrmed these ﬁndings. 
The only study that did not show a survival gain, used T for only nine weeks. Guide-
lines and regulatory agencies recomend the use of T for one year. On the pharmaco-
economic perspective, T has a CER similar or better than other procedures covered 
by the public sector in Brazil, such as heart transplant, tacrolimus for kidney trans-
plantation, ribavirin plus peg-interferon for C hepatitis and bone marrow transplant. 
These procedures have a CER betwen US$35,000 and US$45,000 / QALY (or above). 
The CER of adjuvant T is around US$20,000/QALY. CONCLUSIONS: Trastuzumab 
is indicated for the adjuvant treatment of BCP, and must be considered as standard 
treatment for these patients. Also, from a pharmacoeconomic point of view, it’s CER 
is similiar to other medical interventions covered by the Brazilian health care public 
system.
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OBJECTIVES: To conduct a review of the Health Technology Assessments (HTA) 
recommendations published on the International Network of HTA (INAHTA) website 
concerning the use of capecitabine to treat colorectal cancer in order to support the 
decision making in Brazil. METHODS: A search was conducted on INAHTA website 
(www.inahta.org), in English language, for the key word “capecitabine”. Nineteen 
results were found, from which: 5 referred to other drugs; 6 to other capecitabine 
indication; 1 indicated an ongoing analysis, consequently, 7 results met our objective. 
RESULTS: The economic assessments found were conducted in Europe (6) and Argen-
tina (1). All reports positively recommended the use of capecitabine. In the metastatic 
setting, the assessment made in 2003 by the NHS of Scotland and NICE (England) 
recommended capecitabine as an option for ﬁrst line monotherapy; that of the NIHR 
Health Technology Assessment programme (England, 2003) showed that there are 
cost savings associated with the use of capecitabine and that of the IECS (Argentina, 
2004), concluded that capecitabine could be a therapeutic option with an easier 
administration and better safety proﬁle. In the adjuvant setting, the NHSC (England, 
2003) assessed that capecitabine may have a signiﬁcant beneﬁcial impact on patients, 
health services and staff. In 2006, NICE recommended capecitabine as monotherapy 
for patients with stage III (Dukes’ C) colon cancer following surgery and the NIHR 
Health Technology Assessment programme showed that capecitabine is cost-effective 
in comparison with 5-FU/LV regimens. The authors also suggested that further 
research is necessary to compare effectiveness of capecitabine with other 5-FU/LV 
infusion regimens common used. CONCLUSIONS: According to this review, all 
published economic assessments up to the present date support the use of capecitabine 
for colorectal cancer (metastatic and adjuvant therapy).
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OBJECTIVES: To conduct a review of Health Technology Assessments (HTA) recom-
mendations published on the International Network of HTA (INAHTA) website 
concerning use of capecitabine to treat breast cancer in order to support decision 
making in Brazil. METHODS: A search was conducted on INAHTA website (www.
inahta.org), in English language, for the key word “capecitabine”. Nineteen results 
were found, from which: 5 referred to other drugs; 10 to other capecitabine indica-
tions; consequently, 4 results met our objective. RESULTS: The economic assessments 
found were conducted in Europe (3) and Argentina (1). From these, 3 positively recom-
mend the use of capecitabine for breast cancer and 1 did not state a clear recommenda-
tion, though considering that capecitabine seems to be a cost-effective therapy. The 
analysis conducted in 2003 by the NHS of Scotland for metastatic breast cancer, 
and that of the NICE (England) for locally advanced or metastatic breast cancer were 
replaced by NICE guidance CG81 (2009), which recommended capecitabine as mono-
therapy for second or third line in patients for whom anthracycline-containing 
regimens are unsuitable or have failed. In 2004, the IECS(Argentina), concluded 
that capecitabine can be a therapeutic option for locally advanced or metastatic 
breast cancer combined with docetaxel or as monotherapy. The assessment stated 
that capecitabine should be used when patients failed or are not eligible for anthracy-
cline-containing regimens. The assessment by NIHR Health Technology Assessment 
programme (England, 2004), indicated that capecitabine treatment as monotherapy 
or combined with docetaxel for locally advanced and/or metastatic breast cancer 
appears to be cost-effective. However, the authors stated that the evidence base 
for assessment was poor and further investigation is necessary. CONCLUSIONS: 
According to this review, the published economic assessments up to the present 
date suggest capecitabine as an option for the treatment of breast cancer (locally 
advanced or metastatic) for patients who failed or are not eligible for anthracycline-
containing regimens.
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OBJECTIVES: Since 2004, hospital cares are ﬁnanced by allotted amounts at a 
speciﬁc diagnosis-based level. In order to guarantee access to innovative drugs, high-
cost drugs are gathered on a positive list and are paid out of the budget with a total 
reimbursement under conditions of good use. As hospital drugs prices are free, the 
regulator sets up a reimbursement price cap in 2005, named responsibility tariff (RT), 
to avoid uncontrolled increase of prices due to a low interest in negotiation between 
hospitals and ﬁrms. The aim of this work is to assess the impact of this regulation 
measure on cancer drugs market between 2004 and 2007. METHODS: This study 
uses data from the technical agency of information on hospitals and included establish-
ments previously under ﬁxed global budget. Those data, from 2004 to 2007, provide 
quantities, expenditures and purchase prices of cancer drugs on this list belonging to 
the L01 level of the world health organization anatomical therapeutic and chemical 
classiﬁcation. Furthermore, an index representing the ratio of the purchase prices 
and the RT is built. RESULTS: The consumption of L01 drugs shows an important 
evolution with a 17.2% yearly growth rate between 2005 and 2007. Expenditures 
exceed 1.6 billions of euros in 2007. The contribution of L01 in spending of the high-
cost drugs list reaches 66% in 2006 and 37% in 2007. The RT leads to a transient 
prices decrease in 2005 before an alignment on regulated prices. Only competitive 
market allows low prices under RT. CONCLUSIONS: The rising spending of cancer 
drugs is due to the consumption of recent and expensive drugs. Their rationalization 
implies a strict innovation evaluation. The optimal level of innovation still needs to 
be deﬁned.
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OBJECTIVES: Due to wide variations in prescribing practice, a key methodological 
challenge for an economic analysis in oncology is describing current practice. Robust 
methods of eliciting the full range of expert opinion are necessary to ensure clinical 
relevance and validity of economic models. Insufﬁcient information about variations 
in management can lead to model underestimation of uncertainty. This study aims to 
determine the appropriate model structure for an economic evaluation of a pharma-
cogenetic test to inform irinotecan prescribing, by identifying current practice. 
METHODS: Expert opinion was elicited to inform model structure. Through semi-
structured postal survey (May-August 2008), clinical experts were asked to describe: 
the general management of advanced CRC patients on chemotherapy, place of irino-
tecan-based regimens within the clinical pathway and management of patients on these 
regimens. Since data on the frequency of key adverse events (neutropaenia and 
